EA201000003A1 - Ингибиторы протеинкиназ и способы их применения - Google Patents
Ингибиторы протеинкиназ и способы их примененияInfo
- Publication number
- EA201000003A1 EA201000003A1 EA201000003A EA201000003A EA201000003A1 EA 201000003 A1 EA201000003 A1 EA 201000003A1 EA 201000003 A EA201000003 A EA 201000003A EA 201000003 A EA201000003 A EA 201000003A EA 201000003 A1 EA201000003 A1 EA 201000003A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- raf
- compounds
- inhibitors
- abl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 C-Raf Chemical compound 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 101150053778 CSF1R gene Proteins 0.000 abstract 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 abstract 1
- 101100503636 Danio rerio fyna gene Proteins 0.000 abstract 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 abstract 1
- 108010055334 EphB2 Receptor Proteins 0.000 abstract 1
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 abstract 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 abstract 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 abstract 1
- 101150018272 FYN gene Proteins 0.000 abstract 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 abstract 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 abstract 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 abstract 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 abstract 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 abstract 1
- 101150028321 Lck gene Proteins 0.000 abstract 1
- 101150058160 Lyn gene Proteins 0.000 abstract 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 abstract 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 abstract 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 abstract 1
- 101100354317 Mus musculus Ptk6 gene Proteins 0.000 abstract 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 abstract 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 abstract 1
- 101150083487 SIK1 gene Proteins 0.000 abstract 1
- 101150001535 SRC gene Proteins 0.000 abstract 1
- 101150110875 Syk gene Proteins 0.000 abstract 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 101150060629 def gene Proteins 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94541007P | 2007-06-21 | 2007-06-21 | |
| PCT/US2008/067290 WO2008157575A1 (en) | 2007-06-21 | 2008-06-18 | Protein kinase inhibitors and methods for using thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201000003A1 true EA201000003A1 (ru) | 2010-06-30 |
Family
ID=39682516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201000003A EA201000003A1 (ru) | 2007-06-21 | 2008-06-18 | Ингибиторы протеинкиназ и способы их применения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110053932A1 (enExample) |
| EP (1) | EP2170842A1 (enExample) |
| JP (1) | JP2010530438A (enExample) |
| KR (1) | KR20100035635A (enExample) |
| CN (1) | CN101687821A (enExample) |
| AU (1) | AU2008265843B2 (enExample) |
| BR (1) | BRPI0813216A2 (enExample) |
| CA (1) | CA2691100A1 (enExample) |
| EA (1) | EA201000003A1 (enExample) |
| MX (1) | MX2009013781A (enExample) |
| WO (1) | WO2008157575A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
| JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体 |
| US8394795B2 (en) * | 2008-02-29 | 2013-03-12 | Array Biopharma Inc. | Pyrazole [3, 4-B] pyridine Raf inhibitors |
| AR070535A1 (es) * | 2008-02-29 | 2010-04-14 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos para usarlos |
| US20110003809A1 (en) * | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| US8822500B2 (en) * | 2008-03-19 | 2014-09-02 | Chembridge Corporation | Tyrosine kinase inhibitors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| CN102105150B (zh) | 2008-05-21 | 2014-03-12 | 阿里亚德医药股份有限公司 | 用作激酶抑制剂的磷衍生物 |
| NZ595747A (en) | 2009-03-18 | 2015-06-26 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
| EP2421533B1 (en) | 2009-04-22 | 2018-10-17 | Resverlogix Corp. | Novel anti-inflammatory agents |
| AU2010343102B2 (en) * | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| US8669256B2 (en) | 2010-05-28 | 2014-03-11 | Merck Sharp & Dohme B.V. | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity |
| KR101884010B1 (ko) | 2011-05-04 | 2018-07-31 | 어리어드 파마슈티칼스, 인코포레이티드 | Egfr-유도된 암의 세포 증식을 억제하는 화합물 |
| US10321419B2 (en) | 2011-08-10 | 2019-06-11 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting data using a multi-carrier in a mobile communication system |
| KR101967721B1 (ko) | 2011-08-10 | 2019-04-10 | 삼성전자 주식회사 | 무선 통신 시스템에서 확장 접속 차단 적용 방법 및 장치 |
| EP3429307B1 (en) | 2011-08-10 | 2022-06-15 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting data using a multi-carrier in a mobile communication system |
| KR102247818B1 (ko) | 2011-08-10 | 2021-05-04 | 삼성전자 주식회사 | 이동통신 시스템에서 복수의 캐리어를 이용해서 데이터를 전송하는 방법 및 장치 |
| EP2765806B1 (en) | 2011-10-05 | 2020-09-23 | Samsung Electronics Co., Ltd. | Method and apparatus for reselecting a cell in heterogeneous networks in a wireless communication system |
| BR112014008194B1 (pt) | 2011-10-05 | 2022-01-04 | Samsung Electronics Co., Ltd | Métodos e terminais para pesquisar células vizinhas em um sistema de comunicação móvel |
| EP3349396B1 (en) | 2011-10-10 | 2021-05-05 | Samsung Electronics Co., Ltd. | Method and device for performing random access in a secondary cell |
| US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
| BR112015008389B1 (pt) * | 2012-10-15 | 2020-12-15 | Resverlogix Corp | Compostos úteis na síntese de compostos de benzamida |
| RU2015137610A (ru) | 2013-03-06 | 2017-04-10 | Дженентек, Инк. | Способы лечения и профилактики лекарственной резистентности злокачественных опухолей |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| JP2017517552A (ja) | 2014-06-13 | 2017-06-29 | ジェネンテック， インコーポレイテッド | 抗癌剤耐性の治療及び防止方法 |
| WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| KR102662215B1 (ko) | 2014-11-06 | 2024-05-02 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도 |
| US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| EP3268007B1 (en) | 2015-03-13 | 2022-11-09 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| WO2017066193A1 (en) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
| WO2017176961A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| JP7034935B2 (ja) | 2016-04-06 | 2022-03-14 | リソソーマル・セラピューティクス・インコーポレイテッド | ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| US11192892B2 (en) | 2016-04-06 | 2021-12-07 | Bial—R&D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
| US20190389865A1 (en) * | 2016-05-05 | 2019-12-26 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017192930A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN112979615B (zh) * | 2019-12-17 | 2024-08-09 | 上海医药集团股份有限公司 | 一种喹唑啉脲类化合物、其制备方法、制备中间体、药物组合物及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001021598A1 (en) * | 1999-09-23 | 2001-03-29 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| MXPA02011974A (es) * | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Derivados de quinazolina sustituidos y su uso como inhibidores. |
| AU2003270199A1 (en) * | 2002-09-13 | 2004-04-30 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| KR20070011501A (ko) * | 2004-04-28 | 2007-01-24 | 애로우 쎄라퓨틱스 리미티드 | 항바이러스제로서 유용한 모르폴리닐아닐리노퀴나졸린유도체 |
-
2008
- 2008-06-18 JP JP2010513369A patent/JP2010530438A/ja active Pending
- 2008-06-18 BR BRPI0813216-0A2A patent/BRPI0813216A2/pt not_active IP Right Cessation
- 2008-06-18 US US12/665,894 patent/US20110053932A1/en not_active Abandoned
- 2008-06-18 CN CN200880021088A patent/CN101687821A/zh active Pending
- 2008-06-18 CA CA2691100A patent/CA2691100A1/en not_active Abandoned
- 2008-06-18 AU AU2008265843A patent/AU2008265843B2/en not_active Expired - Fee Related
- 2008-06-18 MX MX2009013781A patent/MX2009013781A/es active IP Right Grant
- 2008-06-18 WO PCT/US2008/067290 patent/WO2008157575A1/en not_active Ceased
- 2008-06-18 EA EA201000003A patent/EA201000003A1/ru unknown
- 2008-06-18 KR KR1020097026460A patent/KR20100035635A/ko not_active Withdrawn
- 2008-06-18 EP EP08771318A patent/EP2170842A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0813216A2 (pt) | 2014-12-23 |
| CN101687821A (zh) | 2010-03-31 |
| US20110053932A1 (en) | 2011-03-03 |
| AU2008265843B2 (en) | 2012-02-09 |
| WO2008157575A1 (en) | 2008-12-24 |
| JP2010530438A (ja) | 2010-09-09 |
| MX2009013781A (es) | 2010-02-01 |
| KR20100035635A (ko) | 2010-04-05 |
| CA2691100A1 (en) | 2008-12-24 |
| AU2008265843A1 (en) | 2008-12-24 |
| EP2170842A1 (en) | 2010-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201000003A1 (ru) | Ингибиторы протеинкиназ и способы их применения | |
| EA200901654A1 (ru) | Ингибиторы и способы с их использованием | |
| ATE499374T1 (de) | Verbindungen und zusammensetzungen als proteinkinase-hemmer | |
| EA201000325A1 (ru) | Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ | |
| MX2008001969A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
| TN2009000145A1 (en) | Compositions and methods for modulating c-kit and pdgfr receptors | |
| MX2010002004A (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa. | |
| MX2007005547A (es) | Compuestos y composiciones como inhibidores de la proteina cinasa. | |
| WO2006124731A3 (en) | Compounds and compositions as protein kinase inhibitors | |
| TNSN06406A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
| WO2008112695A3 (en) | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment | |
| EA200970347A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| WO2007022268A3 (en) | Compounds and compositions as protein kinase inhibitors | |
| TW200637547A (en) | Compounds and compositions as protein kinase inhibitors | |
| EA201300246A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| BRPI0415210A (pt) | compostos e composições como inibidores de proteìna cinase | |
| EA200901483A1 (ru) | ПРОИЗВОДНЫЕ ПИРИМИДИНА И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
| MA38391B1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
| ATE444294T1 (de) | Verbindungen und zusammensetzungen als proteinkinaseinhibitoren | |
| MX2008001605A (es) | Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica. | |
| TH98294A (th) | องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์ |